No disclosed relationships extracted for CNTNyet. The EDGAR pass hasn't reached this filing; the graph grows as filings are read.
Hillstream BioPharma, Inc., a pre-clinical biotechnology company, develops novel therapeutic candidates targeting ferroptosis, an anti-cancer mechanism resulting in iron mediated cell death (IMCD) for the treatment resistant cancers. The company's product candidate is HSB-1216, an IMCD inducer targeting solid tumors. It also develops HSB-888, a dual Quatramer loaded IMCD inducer coupled with its anthracycline analogue for solid tumors; HSB-510, a targeted bifunctional inhibitory compound in Quatramer with single digit nanomolar; IC50 against PI3K-delta and HDAC6, which is also known to downregulate; c-myc, a cancer drug target; and HSB-114, an immunotherapeutic agent, which uses its Quatramer technology to deliver tumor necrosis factor-alpha gene into cancer cells. The company was incorporated in 2019 and is based in Bridgewater, New Jersey.
Nothing on the wire mentions CNTN yet. Iris sweeps the public feeds every quarter hour; headlines land here the moment a sweep tags them.
How CNTN has moved on past release days vs its typical ±5.2% day, and how often it closed up. Computed from daily closes — not a forecast.